Octagon Announces Record Growth in CDISC Engagements
As Octagon experienced significant growth in its CDISC SDTM related business, leaders in clinical data standardization note increased interest in CDISC standards.
Wayne, PA-April 24, 2008-Chief Executive Officer and Chairman Jim Walker of Octagon Research Solutions today announced that the company has experienced significant growth in its Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulations Model (SDTM) related business in recent months.
Dave Evans, chief information officer at Octagon, noted, “This massive upswing in interest in CDISC standards is indicative of a strong industry trend toward standardization across the clinical data lifecycle. Companies are realizing the importance of clinical data standards and how they contribute to the reduction of time and cost within the clinical data lifecycle.”
As the primary trainer for CDISC SDTM for human clinical trials, Octagon has trained more than 2000 registrants representing over 200 different organizations and conducted training in 12 countries throughout North America, Europe, and Asia. To date, the company has completed the conversion of electronic clinical study data to CDISC SDTM format for over 150 studies across eight therapeutic areas and 2500 domains.
Octagon’s CDISC-related services include consulting, data conversions, and data standards governance. These offerings will assist clients in their efforts to implement CDISC data standards, particularly the CDISC SDTM, which is the U.S. FDA’s preferred format for receiving clinical data in an electronic regulatory submission. Octagon’s consultants are often engaged to help clients develop transition strategies and manage their implementations. An increased number of these projects include a forward looking, global focus on data standards governance and the longer-term maintenance of clinical data standards. Octagon offers a packaged solution, ViewPoint® for data standards governance that enables clients to manage and control data standards globally throughout the clinical data lifecycle. As clients continue their transition efforts, they still need to address the conversion of legacy data, which Octagon offers in a business process outsourcing model.
“Octagon’s products and services continue to be recognized within the industry because of our willingness to embrace the transition to new clinical data standards,” noted Walker. “We are taking a leadership position in the electronic clinical data standards arena because we believe the implementation of such standards is critical for the integration and streamlining of clinical and regulatory processes.”
About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading process-centric solutions provider that offers a suite of regulatory, clinical, process, and IT solutions to the life sciences industry. Octagon synchronizes processes and increases automation to reduce island-to-island inefficiencies within the clinical research and development process. The company leverages the power of electronic submissions through deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Berkhamsted, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit
www.octagonresearch.com
.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
